Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, Hong K, McBride J, Shon-Nguyen Q, Xiao Y, Ramakrishnan V, Polson AG, Samineni D, Leipold D, Humke EW, McClellan JS, Berdeja JG. Stewart AK, et al. Among authors: leipold d. Blood Cancer J. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8. Blood Cancer J. 2019. PMID: 30718503 Free PMC article. Clinical Trial.
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Pillow TH, Schutten M, Yu SF, Ohri R, Sadowsky J, Poon KA, Solis W, Zhong F, Del Rosario G, Go MAT, Lau J, Yee S, He J, Liu L, Ng C, Xu K, Leipold DD, Kamath AV, Zhang D, Masterson L, Gregson SJ, Howard PW, Fang F, Chen J, Gunzner-Toste J, Kozak KK, Spencer S, Polakis P, Polson AG, Flygare JA, Junutula JR. Pillow TH, et al. Among authors: leipold dd. Mol Cancer Ther. 2017 May;16(5):871-878. doi: 10.1158/1535-7163.MCT-16-0641. Epub 2017 Feb 21. Mol Cancer Ther. 2017. PMID: 28223423
Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia.
Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, Dere RC, Carrasco-Triguero M, Lee MV, Saad OM, Liu L, He J, Su D, Xu K, Vuillemenot BR, Laing ST, Schutten M, Kozak KR, Zheng B, Polson AG, Kamath AV. Leipold DD, et al. MAbs. 2018 Nov-Dec;10(8):1312-1321. doi: 10.1080/19420862.2018.1517565. Epub 2018 Oct 2. MAbs. 2018. PMID: 30183491 Free PMC article.
Prediction of Human Pharmacokinetics of Antibody-Drug Conjugates From Nonclinical Data.
Li C, Zhang C, Deng R, Leipold D, Li D, Latifi B, Gao Y, Zhang C, Li Z, Miles D, Chen SC, Samineni D, Wang B, Agarwal P, Lu D, Prabhu S, Girish S, Kamath AV. Li C, et al. Among authors: leipold d. Clin Transl Sci. 2019 Sep;12(5):534-544. doi: 10.1111/cts.12649. Epub 2019 Jun 11. Clin Transl Sci. 2019. PMID: 31115997 Free PMC article.
An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models.
Yu SF, Lee DW, Zheng B, Del Rosario G, Leipold D, Booler H, Zhong F, Carrasco-Triguero M, Hong K, Yan P, Rowntree RK, Schutten MM, Pillow T, Sadowsky JD, Dragovich PS, Polson AG. Yu SF, et al. Among authors: leipold d. Mol Cancer Ther. 2021 Feb;20(2):340-346. doi: 10.1158/1535-7163.MCT-20-0046. Epub 2020 Dec 3. Mol Cancer Ther. 2021. PMID: 33273056
Calicheamicin Antibody-Drug Conjugates with Improved Properties.
Vollmar BS, Frantz C, Schutten MM, Zhong F, Del Rosario G, Go MAT, Yu SF, Leipold DD, Kamath AV, Ng C, Xu K, Dela Cruz-Chuh J, Kozak KR, Chen J, Xu Z, Wai J, Adhikari P, Erickson HK, Dragovich PS, Polson AG, Pillow TH. Vollmar BS, et al. Among authors: leipold dd. Mol Cancer Ther. 2021 Jun;20(6):1112-1120. doi: 10.1158/1535-7163.MCT-20-0035. Epub 2021 Mar 15. Mol Cancer Ther. 2021. PMID: 33722856
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P, Sun LL, Clark R, Hristopoulos M, Chiu CPC, Dillon M, Lin W, Lo AA, Chalsani S, Das Thakur M, Zimmerman Savill KM, Rougé L, Lupardus P, Piskol R, Husain B, Ellerman D, Shivva V, Leong SR, Ovacik M, Totpal K, Wu Y, Spiess C, Lee G, Leipold DD, Polson AG. Wang P, et al. Among authors: leipold dd. Mol Cancer Ther. 2022 Jun 1;21(6):974-985. doi: 10.1158/1535-7163.MCT-21-0599. Mol Cancer Ther. 2022. PMID: 35364611 Free PMC article.
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.
Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W. Junutula JR, et al. Among authors: leipold dd. Nat Biotechnol. 2008 Aug;26(8):925-32. doi: 10.1038/nbt.1480. Epub 2008 Jul 20. Nat Biotechnol. 2008. PMID: 18641636
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.
Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J. Jumbe NL, et al. Among authors: leipold dd. J Pharmacokinet Pharmacodyn. 2010 Jun;37(3):221-42. doi: 10.1007/s10928-010-9156-2. Epub 2010 Apr 28. J Pharmacokinet Pharmacodyn. 2010. PMID: 20424896
48 results